Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDA vs Artemether-lumefantrine in Pediatric Malaria
NCT00344006Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of chlorproguanil + dapsone + artesunate in Plasmodium falciparum malaria (2 arms), sponsored by GSK. Primary endpoint: Parasitological cure rate, PCR corrected at 28 days. Started Jun 2006; status: completed.
02
Drugs
chlorproguanil + dapsone + artesunate
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT00344006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00344006.